Specific objectives – Describe the average profile of healthcare

Specific objectives – Describe the average profile of healthcare resource consumption of a retrospective cohort (patients who died from malignant neoplasm) in the last 30 days of life by diagnosis and age group. – Quantify and compare the costs of the use of healthcare resources in the cohorts of patients with and without SAIATU intervention. – Compare quality of life in Inhibitors,research,lifescience,medical the cohorts of patients with and without SAIATU intervention. Methods/design Hypothesis

The intervention of SAIATU (a resource for the social support of end-of-life patients) improves efficiency in the use of healthcare resources in end-of-life patients, decreasing the consumption of hospital resources and increasing the home-based activities conducted by Primary Care in the last 30 days of life. Location and date of study The study will be conducted in the provinces of Guipúzcoa. Period of study: Inhibitors,research,lifescience,medical September 2012 – October 2013. Study design The study was designed in two phases. Phase 1: RETROSPECTIVE study to register a control cohort of patients who died from malignant neoplasm The objective of this study is to determine the baseline risk of the principal variable, consumption of resources in the population of patients Inhibitors,research,lifescience,medical who die from malignant neoplasm. Thus, the study characterises, by primary diagnosis (criteria

and rules established by the International Statistical Classification of Diseases 10 [ICD-10] [26]) and age, the behaviour of different malignant Inhibitors,research,lifescience,medical neoplasms, with regard to resource consumption: number of visits to or consultations with Primary Care, number of external consultations, number of visits to hospital emergency departments, number of hospital admissions, average length of stay, and days in home hospitalisation. Time of study: time series of 4 years, to be determined based on Osakidetza records and the mortality register. Based on the results of this

study and on the hypothesis of the decrease in, and improved efficiency of, resource consumption through the intervention of support programs, formulated as a result of the retrospective observational study carried out, the sample size of cohorts and Inhibitors,research,lifescience,medical subgroups will be defined for Phase 2: PROSPECTIVE cohort study. For this analysis, the error will be established at α=5% with a statistical significance of 80% (error β=20%). The sample size of each subgroup n will be the maximum of the sample sizes obtained for the comparison of means or proportions of Cilengitide the main variables in each subgroup. For the comparison of two means: n=2Zα/2+Zβ∧2*S∧2/d∧2 (1) where: Zα/2=1.960Zβ=0.842 (2) S2=variance in the quantitative variable of the control group d=Minimum value of the difference to be detected (quantitative values) For the comparison of two proportions: n=2p*q∧2Zα/2+Zβ∧2/pA−pB∧2 (3) where: Zα/2=1.960Zβ=0.842 (4) p=Mean of the two proportions pA y pB The parameters will be analysed with the statistical software SPSS 15.0 for Windows.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>